Overview

A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

A Phase 1, First-in-Human, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 in Healthy Volunteers and to Evaluate the Antiviral Activity of MB-110 in Hepatitis C Virus Infected Subjects

Phase:

Phase 1

Details

Lead Sponsor:

Microbio Co Ltd

Treatments:

Antiviral Agents